Skip to main content

Reliance Jio Q1 profit rises over 180% to Rs 2,520 crore, ARPU up 7.4% at Rs 140.3

Jio Platforms helped the company to deleverage balance sheet and became net debt free in June, which was well ahead of targeted date of March 31, 2020.

 

Reliance Jio reported a net profit of Rs 2,520 crore for the June quarter 2020 against a profit of Rs 891 crore in same quarter of last year registering a growth of 183 percent.

The average revenue per user (ARPU) grew a significant 7.4 percent sequentially to Rs 140.3 per subscriber per month. This was much higher than the expected 3.5 percent growth. Work from home boosted data consumption for the wholly-owned subsidiary of billionaire Mukesh Ambani-owned Reliance Industries.


"Consumer facing businesses became the life-line for individuals and businesses with our Retail and Jio teams working hard to ensure millions got essential goods and services through the lockdown," Mukesh Dhirubhai Ambani, Chairman and Managing Director said.

Revenue for the June quarter was at Rs 16,557 crore, increasing 33.7 percent compared to Rs 12,383 crore in same period last year. It was far ahead of CNBC-TV18 poll estimates of Rs 15,800 crore for the quarter.

Work from home (WHF) boosts Jio’s data consumption and despite lockdown restrictions, the subscriber base grew robustly to 398.3 million at the end of June quarter (compared to 388 million in March quarter) as both voice and data traffic surged.

"There has been strong wireless gross addition of 15.1 million during the quarter despite COVID related restrictions across the country. Monthly churn rate for wireless subscribers at only 0.46 percent during the quarter," said Reliance in its BSE filing.

Customer engagement has increased during the quarter with national lockdown driving average wireless data consumption per user per month to 12.1 GB and average voice consumption to 756 minutes per user per month, it added.

Total wireless data traffic during the quarter was at 1,420 crore GB (30.2 percent YoY growth) with strong customer engagement and best-in-class network performance, company said.

Jio's earnings before interest, tax, depreciation and amortisation (EBITDA) at Rs 7,281 crore grew by 55.4 percent year-on-year and margin expanded 613 bps YoY to 44 percent for the quarter ended June 2020.

Jio Platform Limited has raised Rs 1,52,056 crore across 13 investors which includes Facebook, Google, Silver Lake, Vista Equity Partners, General Atlantic, KKR, Mubadala, ADIA, TPG, L Catterton, Public Investment Fund of Saudi Arabia, Intel Capital and Qualcomm.

Of the total investment, company said Jio Platform Limited has already received Rs 1,15,694 crore as subscription amount from ten investors. "Rs 22,981 crore will be retained at Jio Platform to drive future growth."

Reliance Industries, post completion of these investments, would hold 66.48 percent equity stake in Jio Platform on a fully diluted basis, company said.


Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...
Post a Comment
Read more

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...
Post a Comment
Read more